Everolimus + bicalutamide in treatment of CRPC?

A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …

What to do with a man with M0 or M1 disease who is progressing on treatment

Is the addition of enzalutamide (Xtandi) to an LHRH agonist now the appropriate standard of care for a man with M0 or M1 prostate cancer who starts to progress on treatment with an LHRH agonist alone? … READ MORE …

Reduction in prostate size prior to permanent seed prostate brachytherapy

Data from a randomized clinical trial have shown that there is more than one way to reduce the size of a man’s prostate (if such cytoreduction is needed) prior to treatment with permanent, radioactive pellets (permanent, low-dose brachytherapy) for localized prostate cancer. … READ MORE …

STRIVE trial again shows benefits to enzalutamide vs. bicalutamide

Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Combining a TKI with bicalutamide in men with CRPC

We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date. … READ MORE …

A “last word” from the Genitourinary Cancers Symposium

Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE